Biotechnology company Maxion Therapeutics has doubled its at The Works building on Howard Group’s Unity Campus in Cambridge.
The firm, which occupies the 7,644 sq ft suite 4, has signed a lease on suite 5 securing an additional 8,835 sq ft of laboratory and office space.
Maxion is understood to have taken the former space of biotech company Chimeris UK, which had signed a 10-year lease in 2022 at £43 per sq ft.
According to market sources, Maxion has secured the deal until 2033.
The move follows its successful £58m series A funding round earlier this year, with the new space allowing the company to continue scaling its research and development activities.
Arndt Schottelius, chief executive of Maxion, added: “This new space will play an important role in progressing our lead KnotBody programme, MAX001, in preclinical development to target a broad spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.”
Katherine Friend, director for investment and asset management at Howard Group, said: “The ability to provide flexible lab and office space solutions that enable our member companies to scale and stay within the campus, and the wider Cambridge ecosystem, is central to our vision.”
Image © Howard Group
Send feedback to Evelina Grecenko
Follow Estates Gazette
